Introduction Recent controlled trials have assessed the efficacy of phospodiesterase-5 (PDE-5) inhibitors in secondary Raynaud's phenomenon (RP). However, the conclusions are conflicting, and whether ...

Introduction Phosphodiesterase-type 5 inhibitors (PDE5i) are the recommended first-line treatment for erectile dysfunction. Previous systematic reviews and meta-analyses suggest that they are a safe ...

Increasing evidence from cellular studies and animal models indicate protective effects of phosphodiesterase-5 (PDE5) inhibitors, drugs usually reserved as treatments of erectile dysfunction and ...

Objective: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor.

However, the conserved minor venom components, such as snake venom phosphodiesterase (svPDE), remain largely unexplored. Here, we focus on svPDE by genomic and transcriptomic analysis across snake ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

A new study reports that mirodenafil, a newly developed oral phosphodiesterase type 5 (PDE5) inhibitor, is an efficacious and safe treatment for erectile dysfunction (ED). Many men with ED ...

uk-erlangen.de Objectives To investigate the disease-modifying effects of phosphodiesterase 4 (PDE4) inhibition in preclinical models of systemic sclerosis (SSc). Methods We studied the effects of ...

We demonstrated that phosphodiesterase 1A (PDE1A) promoted metastasis and EMT progression of NSCLC. In addition, NSCLC cells overexpressing PDE1A promoted angiogenesis by regulating exosome release.

Topical roflumilast, 0.05%, is under consideration for treating mild to moderate atopic dermatitis in children aged 2-5 years ...

Carboxylic acids have been shown to be good phosphate bioisosteres (Burke and Lee, 2003; Elliott et al., 2012). Yet phosphonic acids could potentially better-replicate cognate TOP1-DNA substrate ...

Specialty pharmacy expands access to an innovative, steroid-free treatment NEW PROVIDENCE, NJ, UNITED STATES, March 3, 2025 /EINPresswire / -- ...